Despite substantial advances in guideline-directed medical therapy, recurrent hospitalization remains a persistent challenge in the management of congestive heart failure (CHF). Fluid overload is ...

Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to ...

ProtoPie has launched ProtoPie AI in Open Beta, introducing a disruptive "Human-in-the-Loop" workflow that combines AI ...

The analysis included 120 veterans (66 years and older) who potentially experienced the gabapentinoid-LD prescribing cascade. HealthDay News — The potential downstream harms in the gabapentinoid ...

Clinicians may fail to recognize common side effects of drugs like gabapentin — which are frequently prescribed for nerve pain — leading them to prescribe unnecessary medications that cause yet more ...

Furosemide, a highly protein-bound organic acid, promotes free water clearance and natriuresis by entering the proximal tubules of the kidneys and blocking the sodium-potassium-chloride ...

Dr Ray O’Connor looks at the latest clinical studies on therapeutics, including beta-lockers and potassium sparing diuretics ...

1. First intranasal loop diuretic approved by the FDA for heart, kidney, and liver disease patients. 2. Clinical trials showed comparable efficacy to intravenous dosing with more convenient outpatient ...